Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016087 | 0.72 | S1PR1 (0.54) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL30301824 | 0.71 | FFAR1 (0.52) | FFAR1L3MBTL1TP53PPARDTSHR | |
| SCHEMBL3590904 | 0.71 | FFAR1 (0.52) | FFAR1L3MBTL1TP53PPARDTSHR | |
| SCHEMBL8449850 | 0.71 | DGAT1 (0.45) | — | |
| SCHEMBL3378446 | 0.70 | SIGMAR1 (0.58) | — | |
| SCHEMBL955851 | 0.70 | SIGMAR1 (0.58) | — | |
| SCHEMBL3379565 | 0.70 | SIGMAR1 (0.58) | — | |
| SCHEMBL2017263 | 0.69 | CYP11B1 (0.40) | — | |
| SCHEMBL5775918 | 0.69 | PDE2A (0.41) | FFAR1HPGDTBXA2RPTGDRPDE2A | |
| SCHEMBL30671703 | 0.68 | KDM4C (0.55) | FFAR1L3MBTL1TP53PPARDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | FFAR1 140/4885L3MBTL1 4241/4885TP53 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.